Tomohisa Baba1, Fumikazu Sakai2, Terufumi Kato3, Masahiko Kusumoto4, Hirotsugu Kenmotsu5, Hiroaki Sugiura6, Junya Tominaga7, Katsunori Oikado8, Masafumi Sata9, Masahiro Endo5, Noriyo Yanagawa10, Shinichi Sasaki11, Tae Iwasawa1, Yoshinobu Saito12, Yutaka Fujiwara13, Yuichiro Ohe4, Naoya Yamazaki4, Takahiko Sakamoto14, Takashi Koshiba14, Kazuyoshi Kuwano15. 1. Kanagawa Cardiovascular & Respiratory Center, Yokohama, Japan. 2. Saitama Medical University International Medical Center, Hidaka, Japan. 3. Kanagawa Cancer Center, Yokohama, Japan. 4. National Cancer Center Hospital, Tokyo, Japan. 5. Shizuoka Cancer Center, Nagaizumi, Japan. 6. Keio University School of Medicine, Tokyo, Japan. 7. Tohoku University School of Medicine, Sendai, Japan. 8. Cancer Institute Hospital, Tokyo, Japan. 9. Jichi Medical University, Tochigi, Japan. 10. Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital, Tokyo, Japan. 11. Juntendo University Urayasu Hospital, Urayasu, Japan. 12. Nippon Medical School Hospital, Tokyo, Japan. 13. Mitsui Memorial Hospital, Tokyo Japan. 14. Ono Pharmaceutical Co., Ltd, Osaka, Japan. 15. The Jikei University School of Medicine, Tokyo, Japan.
Abstract
Aim: To assess the clinical features/imaging characteristics of pneumonitis reported during nationwide nivolumab postmarketing surveillance in Japan. Patients & methods: Clinical and radiological data were collected from pneumonitis cases reported during/after nivolumab treatment for melanoma or non-small-cell lung cancer. The expert central review committee evaluated each case. Results: Among 144 cases analyzed, 91 (63.2%) had radiological patterns considered typical for drug-induced pneumonitis and 53 (36.8%) patients had previously unobserved patterns with one or more atypical features, including 23 cases (16.0%) with ground glass opacity confined to the area around the tumor (peritumoral infiltration). A higher proportion of patients with (vs without) peritumoral infiltration had an antitumor response to nivolumab. Conclusion: Images of nivolumab-induced pneumonitis showed previously unobserved radiological patterns.
Aim: To assess the clinical features/imaging characteristics of pneumonitis reported during nationwide nivolumab postmarketing surveillance in Japan. Patients & methods: Clinical and radiological data were collected from pneumonitis cases reported during/after nivolumab treatment for melanoma or non-small-cell lung cancer. The expert central review committee evaluated each case. Results: Among 144 cases analyzed, 91 (63.2%) had radiological patterns considered typical for drug-induced pneumonitis and 53 (36.8%) patients had previously unobserved patterns with one or more atypical features, including 23 cases (16.0%) with ground glass opacity confined to the area around the tumor (peritumoral infiltration). A higher proportion of patients with (vs without) peritumoral infiltration had an antitumor response to nivolumab. Conclusion: Images of nivolumab-induced pneumonitis showed previously unobserved radiological patterns.
Authors: Kim Melanie Kraus; Caroline Bauer; Benedikt Feuerecker; Julius Clemens Fischer; Kai Joachim Borm; Denise Bernhardt; Stephanie Elisabeth Combs Journal: Cancers (Basel) Date: 2022-06-15 Impact factor: 6.575